Vaxil Bio Ltd

VXL.CA

$0.01

Closing

0.00

1D

▼-40.00%

YTD

Market cap

$1.51M

52 week high

$0.03

52 week low

$0.01

Volume

319,000

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.51M

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

-3.52

Revenue Growth (Annual)

-

52 week high

$0.03

52 week low

$0.01

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a novel drug discovery and development platform based on signal peptides (SPs) to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, is a MUC1 SP-derived vaccine, which completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The Company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The Company exploits the unique properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.